-1%

est. 2Y upside i

HealthcareSeries C

Neko Health is a Swedish health-tech company co-founded in 2018 by Hjalmar Nilsonne and Daniel Ek. Neko's vision is to create a healthcare system that can help people stay healthy through preventive measures and early detection. This requires completely reimagining the patient's experience and incorporating the latest advances in sensors and AI.

Rank

#2325

Sector

Healthcare Technology

Est. Liquidity

~2Y

Data Quality

Data: Low

The current $7B valuation implies an extreme ~320x ARR multiple, making any near-term exit likely a loss for common shareholders.

Last updated: July 19, 2026

Bull (30%)-1%

Exit at 5x forward revenue ($383M) driven by IPO window and category leadership in preventive health scans. Implied upside -94.5% net of dilution.

Base (55%)-1%

Exit at 3.5x forward revenue ($268M) as multiple converges to public comps. Upside -96.2%.

Bear (15%)-1%

Exit at 2x forward revenue ($153M) with multiple compression due to regulatory delays and competition. Upside -97.8%.

Est. time to liquidity~2.0 years

Preference Stack Risk

moderate

Funding Intensity

1464%

Total preferred funding $1.025B represents 14.6% of current valuation; common stock is wiped out in downside scenarios before preferred recovers.

Dilution Risk

low

With $700M raised in Jul 2026, no near-term dilution expected within 2-year horizon.

Secondary Liquidity

none

No secondary market indicates no liquidity for employees pre-IPO.

Questions to Ask at the Interview

Strategic questions based on Neko's data — designed to show you've done your homework.

  • 1

    “How will Neko differentiate from cheaper diagnostic alternatives as it enters the US market?”

  • 2

    “What is the unit economics per scan and how does subscription model change margins?”

  • 3

    “Given the high valuation, what is the path to liquidity for employees and what signal does the lack of secondary market trades send?”

Community

Valuation Sentiment

Our model estimates -1% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.